focus -WSS

focus

author：Wikipedia 2025-08-23 18:38:10 - browse：38

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Chronically ill young patients struggle to find fertility info

explore

WSS

Pig kidney works a record two months in donated body

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Popular nasal decongestant doesn't actually relieve congestion

FDA approves updated Covid vaccines

Food makers to regulators: Ultra

Hospitals consider fixing cancer drug shortages on their own

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Popular nasal decongestant doesn't actually relieve congestion

In Memoriam: Notable people who died in 2023

Private equity could exacerbate cardiology's overuse problem, experts fear

Heart attack and stroke risk calculators need revising

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Anesthesiologist group: stop taking Ozempic before surgery

How a scoliosis diagnosis changed the life of one young dancer

Guidelines to prevent youth baseball injuries need more muscle

Food makers to regulators: Ultra

hotspot

Regeneron agrees to White House price limits on anti

WATCH: Why do bright lights make us see spots?

Hospitals consider fixing cancer drug shortages on their own

U.K. sequencing study surfaces new findings about tumor DNA

Long Covid needs a new name — and a new frame

Why psychiatrists like me stop taking insurance

knowledge

hotspot

explore

focus